Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Healio

March 18, 2018

HIV drug candidate shows promise in ulcerative colitis

Healio

December 20, 2017

ABX464 reduces HIV reservoir

PharmaVoice

November 22, 2017

Trending 2018 : Treatment to Wellness

EBD Group

November 22, 2017

BIO-Europe® 2017: Abivax CEO highlights pipeline assets, including lead HIV drug

BioCentury

October 6, 2017

ABIVAX’S ABX464 REDUCES HIV DNA IN CD4+ T CELLS IN PHASE IIA

  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn